Physician profile
Erlin Javier Marte
NPI 1316204290
$570,347.68
in general payments reported to CMS, 2019-2025
19 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $50K · 2021: $48K · 2022: $85K · 2023: $100K · 2024: $113K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $321K · Travel and Lodging: $33K · Consulting Fee: $12K · Food and Beverage: $8,518 · Education: $64.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $320,822.05 |
| Travel and Lodging | $33,375.20 |
| Consulting Fee | $11,526.00 |
| Food and Beverage | $8,518.06 |
| Education | $64.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $334,281.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $120,144.99 | 2019-2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $88,460.96 | 2020-2025 | |
| Genzyme Corporation | $18,721.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,327.53 | 2019-2021 | |
| Corcept Therapeutics | $331.30 | 2025 | Korlym |
| Horizon Therapeutics Plc | $242.63 | 2023 | Tepezza |
| Mannkind Corporation | $203.45 | 2021-2022 | |
| Amgen INC. | $158.98 | 2024 | Tepezza |
| Janssen Scientific Affairs, LLC | $150.49 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $119.39 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $49.06 | 2022 | |
| Radius Health, INC. | $29.22 | 2020 | |
| Medtronic Minimed, INC. | $23.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.68 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.41 | 2021 | |
| Amneal Pharmaceuticals LLC | $20.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.85 | 2023 | |
| Ibsa Pharma INC. | $19.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erlin Marte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.